GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gufic Biosciences Ltd (BOM:509079) » Definitions » Capex-to-Operating-Cash-Flow

Gufic Biosciences (BOM:509079) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Gufic Biosciences Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Gufic Biosciences's Capital Expenditure for the three months ended in Dec. 2024 was ₹0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2024 was ₹0.00 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Gufic Biosciences Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Gufic Biosciences's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gufic Biosciences Capex-to-Operating-Cash-Flow Chart

Gufic Biosciences Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.85 0.14 0.82 - -

Gufic Biosciences Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gufic Biosciences's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Capex-to-Operating-Cash-Flow falls into.


;
;

Gufic Biosciences Capex-to-Operating-Cash-Flow Calculation

Gufic Biosciences's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Mar. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1126.945) / -74.571
=N/A

Gufic Biosciences's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gufic Biosciences  (BOM:509079) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Gufic Biosciences Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Gufic Biosciences's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Gufic Biosciences Business Description

Traded in Other Exchanges
Address
SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare; Criticare Life; Ferticare; Spark; Herbal and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral and a proton-pump inhibitor. It derives maximum revenue from India.

Gufic Biosciences Headlines

No Headlines